A Phase 1b Trial in Patients With Renal Cell Cancer
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine a safe dose of LY573636-sodium to be given in
combination with sunitinib to patients with metastatic Renal Cell Carcinoma (RCC) and to
determine any side effects that may be associated with LY573636-sodium and sunitinib
combination in this patient population. The tumor response rate will also be assessed.